Table 1. Patient characteristics.

	All patients
	N=87 (%/range)
Median age	56 (27–80)
Tumour type
Ovarian epithelial	80 (92.0)
Fallopian tube	2 (2.3)
Primary peritoneal	5 (5.7)
Stage
II	5 (5.7)
III	48(55.2)
IV	34 (39.1)
BRCA mutation statusa
BRCA1	44 (50.6)
BRCA2	12 (13.8)
Any BRCA mutation	56 (64.4)
Negative	31 (35.6)
History of allergy to medications, environmental factors, foods, and type IV contrast	44 (50.6)
Median platinum-free interval in months	15.9 (5.7–82.4)
Median number of prior carboplatin regimens	2 (0–6)
Median number of prior carboplatin cycles	9 (0–42)
Median number of prior platinum regimensb	2 (1–6)
Median number of prior platinum cyclesb	12 (2–42)

^aOne patient had both BRCA1 and 2 mutation and is counted once in ‘any BRCA mutation' cohort; one patient had a BRCAPro of 68% and is counted in ‘any BRCA mutation' cohort, but not in either of ‘BRCA1' or ‘BRCA2' cohorts.

^bIncludes both carboplatin and cisplatin chemotherapy. One patient received 3 months of oxaliplatin/gemcitabine/cyclophosphamide therapy before enrolment of our trial, but details were not available and excluded from the total platinum calculations.